Online Exclusives

Online Exclusives

Medicare Poised to Cover CAR T-Cell Therapy

Medicare may soon offer coverage of chimeric antigen receptor (CAR) T-cell therapy for patients with cancer, but with considerable restrictions that aim to rein...

PBM Execs Testify Before Congress About High Drug Prices

It was pharmacy benefit managers’ (PBMs’) turn to testify before Congress during an April 9 Senate Finance Committee hearing as part of an ongoing...

CDC: Opioids OK for People With Cancer and Sickle Cell Disease

The Centers for Disease Control and Prevention (CDC) has clarified its 2016 guidelines for opioid prescription, stating that the recommendations were not intended to...

California Hospitals and Lawmakers Clash Over Aid-in-Dying Drugs

Approximately two-thirds of California hospitals restrict physicians’ ability to prescribe aid-in-dying medications, despite a law granting patients with terminal illnesses access to drugs that...

Federal and State Authorities Go After Dangerous Stem Cell Clinics

The U.S. Food and Drug Administration (FDA) and New York’s attorney general have announced new efforts to police for-profit clinics that offer expensive and...

Predatory Publisher Ordered to Pay $50 Million in Damages

OMICS International, which publishes nearly 700 scientific journals, was ordered to pay $50.1 million in damages for engaging in “predatory publisher” tactics. The ruling...

Americans’ Anxiety Over High Health-Care Costs Continues to Grow

There is significant anxiety among Americans about the high costs of health care, according to a recent joint survey by Gallup and West Health. The...

Surprise Medical Bills Receive Bipartisan Scorn

Democrats and Republicans were in rare agreement during an April 2 House subcommittee hearing on the issue of surprise medical bills that result when...

Xarelto Manufacturers Settle Lawsuits Over Bleeding Risks

Johnson & Johnson and Bayer, the manufacturers of rivaroxaban (sold as Xarelto), have agreed to pay $775 million to settle thousands of lawsuits over...

EU Panel Recommends Approving Gene Therapy for Thalassemia

Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Bluebird Bio’s lentiglobin gene-therapy product for patients with transfusion-dependent beta-thalassemia. CHMP is...
Advertisement

Current Issue

April 2019, Volume 5, Issue 5

This issue features a look at the pitfalls of presenting and interpreting clinical trial data, the latest advances in transplant presented at the 2019 TCT Meetings, and more.